Targeting the Wnt/β-catenin signaling pathway in liver cancer stem cells and hepatocellular carcinoma cell lines with FH535

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Gedaly, Roberto ^a   Galuppo, Roberto ^a   Daily, Michael F ^a   Shah, Malay ^a   Maynard, Erin ^a   Chen, Changguo ^a   Zhang, Xiping ^a   Esser, Karyn A ^a   Cohen, Donald A ^a,b   Evers, B Mark ^b   Jiang, Jieyun ^a,b   Spear, Brett T ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ANTINEOPLASTIC AGENT; BETA CATENIN; CYCLIN D1; FH 535; SERINE; SURVIVIN; UNCLASSIFIED DRUG; WNT PROTEIN; BIRC5 PROTEIN, HUMAN; CCND1 PROTEIN, HUMAN; FH535; INHIBITOR OF APOPTOSIS PROTEIN; SULFONAMIDE;

ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CANCER STEM CELL; CELL CYCLE; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; GENE ACTIVATION; GENETIC TRANSFECTION; HEP3B CELL LINE; HUH7 CELL LINE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MUTATION; PLASMID; PLC CELL LINE; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; WILD TYPE; WNT SIGNALING PATHWAY; CARCINOMA, HEPATOCELLULAR; CELL CYCLE CHECKPOINT; DRUG EFFECTS; DRUG SCREENING; GENETICS; LIVER NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOPLASTIC STEM CELLS; SULFONAMIDES; TRANSCRIPTIONAL ACTIVATION; WNT SIGNALING PATHWAY;

EID: 84903289148     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0099272     Document Type: Article

References (39)

1. Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet; 362: 1907-1917. (Pubitemid 37518510)
2. Bosch FX, Ribes J, Díaz M, Cléries R (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology; 127: S5-S16. (Pubitemid 39423365)
3. Welzel TM, Graubard BI, Quraishi S, Zeuzem S, Davila JA, el at (2013) Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am. J. Gastroenterol. 108: 1314-1321.
4. Llovet JM, Bruix J (2008) Molecular targeted therapies in hepatocellular carcinoma. Hepatology; 48:1312-1327.
5. Nambotin SB, Wands JR, Kim M (2011) Points of therapeutic intervention along the Wnt signaling pathway in hepatocellular carcinoma. Anticancer Agents Med. Chem. 11: 549-559.
6. Takigawa Y, Brown AMC (2008) Wnt signaling in liver cancer. Curr. Drug Targets, 9, no. 11:1013-1024.
7. Behrens J, von Kries JP, Kühl M, Bruhn L, Wedlich D, et al (1996) Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 382:638-642. (Pubitemid 26268958)
8. Sun Y, Kolligs FT, Hottiger MO, Mosavin R, Fearon ER, et al (2000) Regulation of beta -catenin transformation by the p300 transcriptional coactivator. Proc. Natl. Acad. Sci. U. S. A. 97:12613-12618.
9. Jennings BH, Ish-Horowicz D (2008) The Groucho/TLE/Grg family of transcriptional co-repressors Genome Biol. 9: 205.
10. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, et al (1998) Identification of c-MYC as a target of the APC pathway. Science 281:1509-1512. (Pubitemid 28425575)
11. Tetsu O, McCormick F (1999). Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398:422-426. (Pubitemid 29180374)
12. Zaffaroni N, Costa A, Pennati M, De Marco C, Affini E, et al (2007) Survivin is highly expressed and promotes cell survival in malignant peritoneal mesothelioma. Cell. Oncol. 29: 453-466. (Pubitemid 350136500)
13. Mikhail S, He AR (2011) Liver cancer stem cells. Int. J. Hepatol. 2011:1-5.
14. Ji J, Wang XW (2012) Clinical implications of cancer stem cell biology in hepatocellular carcinoma. Semin. Oncol. 39: 461-472.
15. Handeli S, Simon JA (2008) A small-molecule inhibitor of Tcf/beta-catenin signaling down-regulates PPARgamma and PPARdelta activities. Mol. Cancer Ther. 7: 521-529. (Pubitemid 351482135)
16. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J (1982) Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res. 42: 3858-3863. (Pubitemid 12054507)
17. Chang J, Hsu Y, Kuo P, Kuo Y, Chiang L, et al (2005) Increase of Bax/Bcl-XL ratio and arrest of cell cycle by luteolin in immortalized human hepatoma cell line. Life Sci. 76:1883-1893. (Pubitemid 40215228)
18. Su SJ, Chow NH, Kung ML, Hung TC, Chang KL (2003) Effects of soy isoflavones on apoptosis induction and G2-M arrest in human hepatoma cells involvement of caspase-3 activation, Bcl-2 and Bcl-XL downregulation, and Cdc2 kinase activity. Nutr. Cancer 45:113-123.
19. Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, et al (1997) Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 275:1784-1787. (Pubitemid 27136714)
20. Orford K, Crockett C, Jensen JP, Weissman AM, Byers SW (1997) Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin. J. Biol. Chem. 272: 24735-24738. (Pubitemid 27415637)
21. Clinkenbeard EL, Butler JE, Spear BT (2012) Pericentral activity of alpha-fetoprotein enhancer 3 and glutamine synthetase upstream enhancer in the adult liver are regulated by b-catenin in mice. Hepatology 56:1892-1901.
22. Fujikawa T, Shiraha H, Nakanishi Y, Takaoka N, Ueda N, et al (2007). Cimetidine inhibits epidermal growth factor-induced cell signaling. J. Gastroenterol. Hepatol. 22:436-443. (Pubitemid 46238777)
23. Ghous Z, Akhter J, Pourgholami MH, Morris DL (2008) Inhibition of hepatocellular cancer by EB1089: in vitro and in vive study. Anticancer Res. 28:3757-3761.
24. Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, et al (2012) PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation. J. Surg. Res. 176:542-548.
25. Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, et al (2010) PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/ Raf/MAPK and PI3K/AKT/mTOR pathways. Anticancer Res. 30: 4951-4958.
26. Godbout R, Tilghman SM (1988) Configuration of the alpha-fetoprotein regulatory domain during development. Genes Dev. 2: 949-956.
27. Groupp ER, Crawford N, Locker J, (1994) Characterization of the distal alpha-fetoprotein enhancer, a strong, long distance, liver-specific activator. J. Biol. Chem. 269: 22178-22187.
28. Yamashita T, Budhu A, Forgues M, Wang XW (2007) Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res. 67: 10831-10839. (Pubitemid 350145912)
29. Gedaly R, Galuppo R, Musgrave Y, Angulo P, Hundley J, et al (2013) PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation. J. Surg. Res. 185:225-230.
30. Palacino JJ,Murphy MP, Murayama O, Iwasaki K, Fujiwara M, et al (2001) Presenilin 1 regulates beta-catenin-mediated transcription in a glycogen synthase kinase-3-independent fashion. J. Biol. Chem. 276:38563-38569.
31. Huang SMA, Mishina YM, Liu S, Cheung A, Stegmeier F, et al (2009) Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461:614-620.
32. Olmeda D, Castel S, Vilaró S, Cano A (2003) Beta-catenin regulation during the cell cycle: implications in G2/M and apoptosis. Mol. Biol. Cell. 14:2844-2860. (Pubitemid 36871526)
33. Shi Z, Qian X, Li L, Zhang J, Zhu S, et al (2012) Nuclear translocation of bcatenin is essential for glioma cell survival. J. Neuroimmune Pharmacol. 7: 892-903.
34. Fabregat I (2009) Dysregulation of apoptosis in hepatocellular carcinoma cells. World J. Gastroenterol. 15:513-520.
35. Hui AM, Makuuchi M, Li X (1998) Cell cycle regulators and human hepatocarcinogenesis. Hepatogastroenterology 45:1635-1642. (Pubitemid 28515174)
36. Whitfield JF (2009). Calcium, calcium-sensing receptor and colon cancer. Cancer Lett. 275: 9-16.
37. Tong CM, Ma S, Guan XY (2011) Biology of hepatic cancer stem cells. J. Gastroenterol. Hepatol. 26:1229-1237.
38. Wachter J, Neureiter D, Alinger B, Pichler M, Fuereder J, et al (2012) Influence of five potential anticancer drugs on wnt pathway and cell survival in human biliary tract cancer cells. Int. J. Biol. Sci. 8:15-29.
39. López-Terrada D, Cheung SW, Finegold MJ, Knowles BB (2009) Hep G2 is a hepatoblastoma-derived cell line. Hum. Pathol. 40:1512-1515.